Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis.
about
Utilization of animal models to investigate non-alcoholic steatohepatitis-associated hepatocellular carcinomaSystematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated reviewImmunotherapeutic approaches for hepatocellular carcinomaSystematic review with network meta-analysis: statins and risk of hepatocellular carcinomaSystematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy.Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection.Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinomaA mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients.HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K/AKT signal pathway.(-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma.R-spondin 2 promotes proliferation and migration via the Wnt/β-catenin pathway in human hepatocellular carcinoma.Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma.
P2860
Q26748807-8F56A4F5-58D2-4C0C-8750-6C9DDEBDED90Q26768128-5F71CB9C-A697-4988-A054-697A41DB437AQ33567018-A01A0883-5DA7-4E47-8BD4-8D8DAB82A986Q33779723-9088DB70-9CE4-4D42-9297-95C0E3C5A511Q35946029-86B0BDDC-8972-433E-8452-F1EFA3360658Q36001152-6A2DF47E-077F-4E71-99BB-85833FA8396EQ36322143-7D82D829-4BC3-4608-8DA0-9875F2C91828Q36905681-A21774A5-125E-4042-B5A8-3AF562C9F115Q37565482-9BE6EB13-540D-48AE-B84F-97038BCEB314Q37706378-A22A35F0-0E31-4D50-9339-5053DD25DC15Q38727305-35C1F8AB-14CC-437C-967C-0377351777F8Q39711667-AB222287-277C-4663-A0EA-3D59982ECFC0Q41142284-FF18CB0D-4990-4AB0-9F69-7878D267E08EQ55333212-B23BCDB4-CBF0-4020-96FF-60D2334EF0B6
P2860
Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Optimal adjuvant therapy for r ...... ew with network meta-analysis.
@ast
Optimal adjuvant therapy for r ...... ew with network meta-analysis.
@en
type
label
Optimal adjuvant therapy for r ...... ew with network meta-analysis.
@ast
Optimal adjuvant therapy for r ...... ew with network meta-analysis.
@en
prefLabel
Optimal adjuvant therapy for r ...... ew with network meta-analysis.
@ast
Optimal adjuvant therapy for r ...... ew with network meta-analysis.
@en
P2093
P2860
P31
P50
P921
P356
P1433
P1476
Optimal adjuvant therapy for r ...... ew with network meta-analysis.
@en
P2093
Hua-Jian Yu
Martin Braddock
Meng-Tao Zhou
Sun-Yue He
Yong-Ping Chen
P2860
P304
18151-18161
P356
10.18632/ONCOTARGET.4098
P407
P5008
P577
2015-06-08T00:00:00Z
2015-07-20T00:00:00Z